{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000031","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.162597+00:00","generated_at":"2026-06-15T13:45:01.079841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Krystal Biotech Q1 net loss $45.3M, cash $355.5M, PDUFA date May 19 for B-VEC","bullets":["Net loss of $45.3M ($1.76 per share) vs $50.0M loss ($1.99) in Q1 2022.","Cash, equivalents & investments $355.5M at March 31, 2023.","R&D expense $12.3M (up from $9.3M); G&A expense $24.0M (up from $15.9M).","PDUFA date for B-VEC Biologics License Application is May 19, 2023; labeling discussions started in April.","Topical B-VEC in eye under compassionate use showed vision improvement from hand motion to 20/40 at 7 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000031","json":"https://secwatch.observer/filing/0001711279-23-000031.json","markdown":"https://secwatch.observer/filing/0001711279-23-000031.md","text":"https://secwatch.observer/filing/0001711279-23-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/0001711279-23-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/krys-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:45:01.079841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af5822f96a71ab840163f402988e5ae2081803dc","claim":"Krystal Biotech, Inc. reported the quarter ended March 31, 2023 results: net income Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),, EPS $(1.76) and $(1.99), respectively, per common share (basic and diluted).","evidence_excerpt":"Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99), respectively, per common share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/0001711279-23-000031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),"},{"label":"EPS","value":"$(1.76) and $(1.99), respectively, per common share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}